Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fumihiko Matsuno

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
International Journal of Cancer|November 26, 2003
Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cellsXinwei She, Fumihiko Matsuno, Naoko Harada, et al.
Haematologica|January 29, 2003
Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cellsShima Uneda, Fumihiko Matsuno, Takashi Sonoki, et al.
British Journal of Haematology|December 21, 2002
Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MMShima Uneda, Hiroyuki Hata, Fumihiko Matsuno, et al.
American Journal of Hematology|April 22, 2006
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemiaHiro Tatetsu, Norio Asou, Miki Nakamura, et al.
Leukemia Research|January 17, 2024
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79bBen K Seon, Morihiro Okazaki, Jill Duzen, et al.
British Journal of Haematology|February 13, 2003
A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse modelShima Uneda, Hiroyuki Hata, Fumihiko Matsuno, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 23, 2003
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]Hiro Tatetsu, Norio Asou, Miki Nakamura, et al.
Molecular Cancer Therapeutics|July 16, 2005
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent mannerHiro Tatetsu, Yutaka Okuno, Miki Nakamura, et al.
Leukemia Research|May 13, 2008
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factorHiro Tatetsu, Fumihiko Matsuno, Noritaka Takatsu, et al.
International Journal of Hematology|July 30, 2009
Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patientsJyuri Watanuki, Kinta Hatakeyama, Takashi Sonoki, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
International Journal of Cancer|November 26, 2003
Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cellsXinwei She, Fumihiko Matsuno, Naoko Harada, et al.
Haematologica|January 29, 2003
Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cellsShima Uneda, Fumihiko Matsuno, Takashi Sonoki, et al.
British Journal of Haematology|December 21, 2002
Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MMShima Uneda, Hiroyuki Hata, Fumihiko Matsuno, et al.
American Journal of Hematology|April 22, 2006
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemiaHiro Tatetsu, Norio Asou, Miki Nakamura, et al.
Leukemia Research|January 17, 2024
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79bBen K Seon, Morihiro Okazaki, Jill Duzen, et al.
British Journal of Haematology|February 13, 2003
A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse modelShima Uneda, Hiroyuki Hata, Fumihiko Matsuno, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 23, 2003
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]Hiro Tatetsu, Norio Asou, Miki Nakamura, et al.
Molecular Cancer Therapeutics|July 16, 2005
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent mannerHiro Tatetsu, Yutaka Okuno, Miki Nakamura, et al.
Leukemia Research|May 13, 2008
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factorHiro Tatetsu, Fumihiko Matsuno, Noritaka Takatsu, et al.
International Journal of Hematology|July 30, 2009
Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patientsJyuri Watanuki, Kinta Hatakeyama, Takashi Sonoki, et al.
Pageof 2